FCA Action’s ‘Fraud-On-The-FDA’ Claims Should Not Proceed to Trial, 1st Cir. Affirms



DOCUMENTS
  • Opinion


BOSTON — A federal appeals court has upheld rejection of a proposed amended complaint accusing the makers of two medical devices of violating the False Claims Act, ruling that the plaintiff’s allegations fall within the “fraud-on-the-FDA” category of claims that have been barred by the U.S. Supreme Court.

In a Dec. 23 opinion, the 1st Circuit U.S. Court of Appeals ruled that allowing the case to proceed to trial could allow a jury to undercut the FDA’s regulatory authority.

Ev3 Inc. and its subsidiary, Micro Therapeutics Inc., manufacture the Onyx Liquid Embolic System and the Axium Detachable Coil System. Onyx …






UPCOMING CONFERENCES




HarrisMartin's MDL Conference: Video Game Addiction and the Latest Mass Tort Updates

May 29, 2024

MORE DETAILS



HarrisMartin's Mass Tort Settlements Conference - Sponsored by Milestone

June 27, 2024 - Buffalo, NY
The Richardson Hotel Buffalo

MORE DETAILS